We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SDZ:SIXSandoz Group Ltd Analysis

Data as of 2026-06-30 - not real-time

$91.04

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Sandoz Group AG is trading at $91.04, comfortably above its 20‑day ($84.29), 50‑day ($83.53) and 200‑day ($75.61) simple moving averages, signalling a strong bullish momentum. The RSI of 68.6 points to near‑overbought conditions, while a bullish MACD crossover (line 1.84 above signal 1.04) reinforces the upward bias. Price is perched at the calculated resistance of $91.04 with support near $79.28, and the recent decline in volume suggests a potential short‑term consolidation. Volatility over the past 30 days is elevated at roughly 26%, indicating sizable price swings. Fundamentally, the company posted 10.7% revenue growth and a forward EPS forecast of $4.62, reflecting solid top‑line expansion. However, a trailing P/E of 43.6 versus an industry average of 25.9, coupled with a DCF‑derived fair value of $35.64, paints a picture of significant overvaluation. Margins are respectable (gross 47.5%, operating 14.3%) and free cash flow of $0.92 bn supports a dividend yield of 1.12% with a payout ratio near 35%, suggesting dividend sustainability. The balance sheet shows a debt‑to‑equity of 60.7% and ample cash reserves, but the high valuation and market‑wide regulatory pressures temper enthusiasm. In summary, while technicals are bullish, the disconnect between price and intrinsic value, combined with sector‑specific risks, advises caution.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price at resistance with limited upside
  • Bullish technical setup but decreasing volume
  • Elevated short‑term volatility

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strong revenue growth and cash flow generation
  • Overvaluation relative to DCF and peers
  • Sustainable dividend payout

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Persistent price‑to‑earnings premium
  • Potential regulatory headwinds in generic drug market
  • High valuation leaving limited margin for upside

Key Metrics & Analysis

Financial Health

Revenue Growth10.70%
Profit Margin8.19%
P/E Ratio43.6
ROE10.42%
ROA4.31%
Debt/Equity60.73
P/B Ratio4.2
Op. Cash Flow$1.6B
Free Cash Flow$924.6M
Industry P/E25.9

Technical Analysis

TrendBullish
RSI68.6
Support$79.28
Resistance$91.04
MA 20$84.29
MA 50$83.53
MA 200$75.61
MACDBullish
VolumeDecreasing
Fear & Greed Index89.91

Valuation

Fair Value$35.64
Target Price$91.40
Upside/Downside0.40%
GradeOvervalued
TypeGrowth
Dividend Yield1.12%

Risk Assessment

Beta0.72
Volatility26.12%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.